Decline in FEV₁ and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency

References

• Laurell C-B, Eriksson S. The electrophoretic α-1-globulin pattern of serum in a α-1-antitrypsin deficiency. Scand J Clin Lab Invest. 1963;15:132–140. doi:10.1080/00365516309051324
   Web of Science ®Google Scholar
• American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818–900. doi:10.1164/rccm.168.7.81814522813
   PubMed Web of Science ®Google Scholar
• Tanash HA, Nilsson PM, Nilsson JA, Piitulainen E. Survival in severe alpha-1-antitrypsin deficiency (PiZZ). Respir Res. 2010;11:44. doi:10.1186/1465-9921-11-6220420704
   PubMed Web of Science ®Google Scholar
• Tanash HA, Nilsson PM, Nilsson JA, Piitulainen E. Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). Thorax. 2008;63:1091–1095. doi:10.1136/thx.2008.09549718682522
   PubMed Web of Science ®Google Scholar
• Wise RA. The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression. Am J Med. 2006;119(10 Suppl 1):4–11. doi:10.1016/j.amjmed.2006.08.002
   PubMed Web of Science ®Google Scholar
• Fletcher C, Peto R. The natural history of chronic airway obstruction. BMJ. 1977;1:1645–1648.871704
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Wright EC, Hodgkin JE; The IPPB Trial Group. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986;133:14–20. doi:10.1164/arrd.1986.133.4.6183510578
   PubMed Web of Science ®Google Scholar
• Burrows B. Predictors of loss of lung function and mortality in obstructive lung diseases. Eur Respir Rev. 1991;1:340–345.
   Google Scholar
• Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–852. doi:10.1136/thorax.57.10.84712324669
   PubMed Web of Science ®Google Scholar
• Makris D, Moschandreas J, Damianaki A, et al. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med. 2007;101(6):1305–1312. doi:10.1016/j.rmed.2006.10.01217112715
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease [www.goldcopd.com]. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2018 report. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf Accessed 116, 2019
   Google Scholar
• Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in alpha-1-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med. 2001;164:1805–1809. doi:10.1164/ajrccm.164.10.210603611734427
   PubMed Web of Science ®Google Scholar
• Fähndrich S, Bernhard N, Lepper PM, et al. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV1 in individuals with PiZZ alpha-1-antitrypsin deficiency. Respir Med. 2017;129:8–15. doi:10.1016/j.rmed.2017.05.01128732839
   PubMed Web of Science ®Google Scholar
• Needham M, Stockley RA. Exacerbations in α1-antitrypsin deficiency. Eur Respir J. 2005;25:992–1000. doi:10.1183/09031936.05.0007470415929953
   PubMed Web of Science ®Google Scholar
• Seersholm N. Kok-Jensen A, Dirksen A. Decline in FEV1 among patients with severe hereditary α1-antitrypsin deficiency type PiZ. Am J Respir Crit Care Med. 1995;152:1922–1925. doi:10.1164/ajrccm.152.6.85207568520756
   PubMed Web of Science ®Google Scholar
• Piitulainen E, Eriksson S. Decline in FEV1 related to smoking status in individuals with severe α1-antitrypsin deficiency (PiZZ). Eur Respir J. 1999;13:247–251.10065663
   PubMed Web of Science ®Google Scholar
• Hutchison DCS, Cooper D. Alpha-1-antitrypsin deficiency: smoking, decline in lung function and implications for therapeutic trials. Respir Med. 2002;96:872–880.12418584
   PubMed Web of Science ®Google Scholar
• Burdon JGW, Brenton S, Hocking V, et al. Decline in FEV1 in patients with PiZ alpha-1-antitrypsin deficiency: the Australian experience. Respirology. 2002;7:51–55.11896901
   PubMed Web of Science ®Google Scholar
• The Alpha-1-antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of α1-antitrypsin. Am J Resp Crit Care Med. 1998;158:49–59. doi:10.1164/ajrccm.158.1.97120179655706
   PubMed Web of Science ®Google Scholar
• Dawkins PA, Dawkins CL, Wood AM, Nightingale PG, Stockley JA, Stockley RA. Rate of progression of lung function impairment in α1-antitrypsin deficiency. Eur Respir J. 2009;33:1338–1344. doi:10.1183/09031936.0006120819164359
   PubMed Web of Science ®Google Scholar
• Piitulainen E, Tanash HA. The clinical profile of subjects included in the Swedish National Register on individuals with severe alpha 1-antitrypsin deficiency (PiZZ). Copd. 2015;12(Suppl):36–41. doi:10.3109/15412555.2015.102190925938290
   PubMedGoogle Scholar
• Quanjer PH. Standardized lung function testing. Report working party. Bull Eur Physiopathol Respir. 1983;19(Suppl 5):1–95.6616097
   PubMedGoogle Scholar
• Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450. doi:10.1186/1471-2458-11-45021658213
   PubMed Web of Science ®Google Scholar
• World Health Organization & International Conference for the Ninth Revision of the International Classification of Diseases (1975:Geneva). Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death: Based on the Recommendations of the Ninth Revision Conference, 1975, and Adopted by the Twenty-Ninth World Health Assembly, 1975 Revision. Vol. 1 Geneva: World Health Organization; 1977 Available from: http://apps.who.int/iris/handle/10665/40492. Accessed 35, 2018.
   Google Scholar
• World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Vol. 1 Geneva: World Health Organization; 1992.
   Google Scholar
• Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:964–974. doi:10.2307/2529876
   Web of Science ®Google Scholar
• Jennrich RI, Schluchter MD. Unbalanced repeated measures models with structured covariance matrices. Biometrics. 1996;42:805–820. doi:10.2307/2530695
   Web of Science ®Google Scholar
• Gladysheva E, Malhotra A, Owens R. Influencing the decline of lung function in COPD: use of pharmacotherapy. Int J COPD. 2010;5:153–164.
   Google Scholar